- Investing.com
Pipeline Progress | Explore Nuvalent's advancing oncology pipeline, with zidesamtinib and neladalkib showing promise in ROS1 and ALK-positive NSCLC clinical trials |
Market Potential | Delve into Nuvalent's strategy to capture both treatment-experienced and first-line markets, potentially positioning it as a leader in targeted therapies |
Financial Outlook | Analysts maintain a positive stance with a $100 price target, despite current unprofitability. EPS projections for FY2025 stand at -$5.07 |
Competitive Edge | Learn how Nuvalent's focus on improved safety profiles and efficacy could differentiate its therapies in the crowded oncology landscape |
Metrics to compare | NUVL | Peers Peers - average of corresponding metrics from companies closely matching NUVL: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipNUVLPeersSector |
|---|---|---|---|---|
P/E Ratio | −21.9x | 0.0x | −0.4x | |
PEG Ratio | 0.59 | 0.00 | 0.00 | |
Price/Book | 8.4x | 0.0x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 50.8% | |
Fair Value Upside | Unlock | 0.0% | 9.4% | Unlock |